Table II.

Multivariate analysis of 5-year progession-free survival in 238 confirmed ovarian carcinoma patients.

Factors	HR	95% CI	P-value
ZEB1 expressiona	1.491	1.063–2.091	0.021
Ageb	1.104	0.961–1.269	0.163
Differentiationc	1.379	1.052–1.808	0.020
FIGO staged	1.689	1.334–2.140	<0.001
Histological subtypee	0.905	0.811–1.267	0.905

^aIncluding negative and positive groups.

^b≤39 vs. 40–49 vs. 50–59 vs. 60–69 vs. ≥70 years.

^cHigh vs. moderate vs. poor differentiation.

^dStage I vs. II vs. III vs. IV.

^eSerous vs. mucinous vs. endometrioid vs. clear-cell vs. mixed epithelial vs. undifferenciated. ZEB1, zinc finger E-box-binding homeobox factor 1; HR, hazard ratio; CI, confidence interval.